PAHO and Unitaid secure first region-wide HPV testing access agreements for Latin America and the Caribbean

By Pan American Health Organization • Nov 16, 2026

The Pan American Health Organization (PAHO) has negotiated the first-ever region-wide access agreements for human papillomavirus (HPV) testing across Latin America and the Caribbean, with support from Unitaid, according to a press release. Announced on 11 November 2026 from Washington, D.C. and Geneva, the deals will allow millions of women to access more affordable, high-quality HPV testing through PAHO’s Regional Revolving Funds. Participating countries are expected to realize cost savings ranging from 30% to 70%. Unitaid will also advance implementation activities in selected countries. The arrangements aim to accelerate progress toward cervical cancer elimination in the region.

HPV infection causes nearly all cases of cervical cancer, which kills more than 40,000 women in the region each year. The disease is highly preventable through vaccination, screening, and timely treatment. Until now, countries across Latin America and the Caribbean have faced some of the highest HPV test prices in the world. PAHO/WHO has recommended HPV testing in cervical cancer screening programs since 2013, with updated guidance issued in 2026. Uptake, however, has been limited due to financial, technical, and programmatic barriers.

Under the new agreements, countries can access high-quality molecular HPV tests through preferential pricing and a comprehensive support package. The arrangements expand the range of WHO-recommended molecular HPV testing technologies available through PAHO’s Revolving Funds under harmonized conditions. The agreements also include implementation support, equipment access, training, maintenance, and technical assistance. These components are designed to reduce operational barriers that have often limited the introduction of new diagnostic technologies. Unitaid will support implementation in El Salvador, Guatemala, Grenada, Saint Vincent and the Grenadines, and Saint Lucia.

“Through PAHO’s Revolving Funds, countries now have access to high-quality HPV testing under more favorable conditions, helping accelerate efforts to eliminate cervical cancer in the Americas,” said PAHO Director Dr. Jarbas Barbosa.

He added that the agreements reflect PAHO’s commitment to working with Member States and partners to expand equitable access to essential health technologies. Molecular tests directly detect high-risk HPV types responsible for most cervical cancer cases. They perform better than other screening methods and can use self-collected samples. The ESTAMPA study, conducted in Latin America, found HPV testing detected nearly all cases of precancerous lesions and invasive cancer, while cytology identified fewer than half.

Expanding HPV testing is key to advancing the WHO’s 90-70-90 cervical cancer elimination targets. Currently, 16 countries and territories in Latin America and the Caribbean have introduced HPV testing in their screening programs, though coverage remains limited by cost. The new access forms part of PAHO’s Disease Elimination Initiative and the Better Care for NCDs initiative. Unitaid’s cervical cancer efforts in Latin America are made possible through contributions from the Government of Japan. Additional support comes from Unitaid’s core donors Brazil, Chile, France, the Gates Foundation, Norway, Portugal, the Republic of Korea, Spain, and the United Kingdom.

Share